Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX Laboratories (NASDAQ: IDXX) announced CEO Mike Erickson will join a fireside chat at the Stifel Jaws & Paws Conference on May 27, 2026, from 10:55–11:25 am (ET), with a live and archived webcast.
The company will also host its 2026 Investor Day on August 13, 2026, 8:00 am–12:00 pm (ET), at its Westbrook, Maine headquarters, with a webcast and advance registration required for in-person institutional investors and analysts.
IDEXX Laboratories (NASDAQ: IDXX) reported Q1 2026 revenue of $1,141M, up 14% reported and 11% organic. Q1 EPS was $3.47, up 17% reported and 15% comparable. Company raised 2026 revenue guidance to $4,675M–$4,760M and EPS to $14.45–$14.90, citing stronger CAG Diagnostics recurring revenue and updated FX assumptions.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2026 first quarter financial results on Tuesday, May 5, 2026, before the market opens.
An analyst conference call begins at 8:30 a.m. ET with a live webcast, prepared remarks transcript, and a Q1 2026 Earnings Snapshot available at www.idexx.com/investors.
An archived webcast will be posted after 1:00 p.m. ET on May 5 and remain available for one year. The live call is reachable by phone at 1-800-330-6730 or 1-213-279-1575 using passcode 492760.
IDEXX (NASDAQ: IDXX) announced UK availability of the IDEXX Cancer Dx Panel starting April 1, 2026, with lymphoma screening for at-risk dogs. Veterinarian pricing starts at £22.50 and results return in 3–5 business days. The blood test reports 79% sensitivity and 99% specificity and can detect a lymphoma signal up to eight months before clinical signs.
The panel integrates with wellness and sick-pet workflows, includes consult access to IDEXX medical specialists, and is available via IDEXX Reference Laboratories in the UK.
IDEXX Laboratories (NASDAQ: IDXX) will participate in two investor conferences in late February and early March 2026. A fireside chat with Mike Lane and Andrew Emerson is scheduled for Feb 26, 9:55–10:30 AM ET at the virtual BofA Securities Animal Health Summit. Jay Mazelsky will present on Mar 2, 9:15–9:45 AM ET at the Raymond James Institutional Investors Conference. Live webcasts and archived editions will be available through the company's investor website at www.idexx.com/investors.
IDEXX Laboratories (NASDAQ: IDXX) reported strong Q4 2025 results with revenue of $1,091M (+14% reported, +12% organic) and EPS of $3.08 (+18% reported, +17% comparable). Full-year revenue was $4,304M (+10%) and EPS $13.08 (+23% reported). The company recorded record instrument placements (including >1,900 IDEXX inVue Dx) and expanded margins; 2026 guidance targets revenue of $4,632M–$4,720M and EPS of $14.29–$14.80.
IDEXX (NASDAQ: IDXX) launched the ImageVue DR50 Plus digital imaging system on January 15, 2026, a connected veterinary radiography solution offering AI-powered imaging and integrated workflows. The system claims up to 25% lower radiation versus IDEXX’s prior DR50 and up to 60% lower radiation versus other veterinary systems, plus a new 17" x 17" panel option. Features include automated image optimization, irradiated side sampling to reduce retakes, IDEXX Web PACS integration, AI hanging protocols and vertebral heart scores, direct Telemedicine submission to 160+ board-certified specialists, and a claimed >45% reduction in clicks to submit cases. Available in the United States and Canada.
IDEXX (NASDAQ: IDXX) announced expansion of its Cancer Dx Panel to include canine mast cell tumor detection, available mid‑year 2026 in the United States and Canada, and rollout of inVue Dx FNA cytology with mast cell tumor detection beginning late Q4 2025 in the U.S. Combined, mast cell tumor and lymphoma detection will address over one‑third of canine cancer cases. The Cancer Dx Panel is used by >5,500 practices in North America and can detect lymphoma up to eight months before clinical signs. Cancer Dx results return in 2–3 days (Canada 2–4 days). inVue Dx FNA offers rapid, slide‑free in‑clinic cytology with optional expert pathologist review.
IDEXX (NASDAQ: IDXX) announced a planned CEO succession: Michael Erickson, PhD, will become President and CEO effective May 12, 2026, and will join the Board upon assuming the role. Current President and CEO Jonathan (Jay) Mazelsky will transition to Executive Chair at that time and has said he will retire following the Company’s annual meeting of shareholders in May 2027. The company described an extended transition with Mazelsky working closely with Erickson to support continuity. Erickson joined IDEXX in 2011 and has held senior roles across diagnostics, software, strategy, and corporate accounts.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2025 fourth quarter and full year financial results on Monday, February 2, 2026 before market open. An analyst conference call will begin at 8:30 a.m. ET that day and will be available via a live webcast, telephone, and an archived webcast posted after 1:00 p.m. ET that will remain available for one year.
Investors can access the live webcast, a transcript of prepared remarks, and a Q4 2025 Earnings Snapshot from the company investor site at www.idexx.com/investors. To join the live call by phone dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 263206.